'Myriad' Patent Issues at Stake as High Court Conferences
By Marie Powers
Staff Writer
Staff Writer
Thursday, November 29, 2012
At Friday's conference session, the Supreme Court will consider for the second time whether to grant cert to Association for Molecular Pathology v. Myriad Genetics Inc., a challenge to the Salt Lake City-based company's claims on the BRCA1 and BRCA2 genes used in diagnostics for breast and ovarian cancers.
To continue reading subscribe now to Latest News
Learn More about Latest News
Already a subscriber? Sign In or Buy now to activate your subscription
Note: our contact information has changed
Customer Care: http://support.clarivate.com
© 2018 Clarivate Analytics.
Reproduction, reposting content is strictly prohibited.
Reproduction, reposting content is strictly prohibited.